A 28-year-old woman with bipolar I disorder has been on haloperidol 10 mg daily for 3 weeks following an acute manic episode. She now presents with involuntary orofacial grimacing, tongue protrusion, and lip smacking that started 2 days ago. She denies fever, rigidity, or altered mental status. Creatine kinase is normal. What is the most appropriate immediate management?

Explanation

## Acute Orofacial Dyskinesia: Recognition and Management ### Clinical Diagnosis This patient presents with **acute orofacial dyskinesia** (not tardive dyskinesia), characterized by: - Involuntary orofacial movements (grimacing, tongue protrusion, lip smacking) - Onset within days to weeks of antipsychotic initiation - Normal CK (rules out neuroleptic malignant syndrome) - Absence of fever, rigidity, altered mental status (rules out NMS) **Key Point:** Acute dyskinesia is a dose-dependent, reversible extrapyramidal side effect that occurs early (days to weeks) with first-generation antipsychotics, particularly high-potency agents like haloperidol. ### Pathophysiology Haloperidol's potent D2 antagonism in the basal ganglia disrupts the balance between dopaminergic and cholinergic activity: - Dopamine blockade → relative cholinergic excess - Basal ganglia disinhibition → involuntary movements Unlike tardive dyskinesia (which develops after months to years and is often irreversible), acute dyskinesia responds rapidly to anticholinergics or agent discontinuation. ### Management Algorithm ```mermaid flowchart TD A[Acute dyskinesia on FGA]:::outcome --> B{Severity?}:::decision B -->|Mild| C[Add anticholinergic: benztropine/trihexyphenidyl]:::action B -->|Moderate-Severe| D[Discontinue FGA, switch to SGA]:::action C --> E[Reassess in 24-48 hours]:::decision E -->|Resolved| F[Continue with anticholinergic cover]:::action E -->|Persistent| D D --> G[Start SGA: quetiapine, olanzapine, or aripiprazole]:::action G --> H[Symptoms resolve within days]:::outcome ``` **High-Yield:** In this case, because the dyskinesia is orofacial (involving muscles of speech and swallowing), it carries risk of aspiration and functional impairment. **Switching to a second-generation antipsychotic is the most appropriate immediate step**, as it addresses the underlying cause and prevents recurrence. ### Why Not Anticholinergics Alone? | Approach | Rationale | Outcome | |----------|-----------|----------| | Add benztropine, continue haloperidol | Anticholinergics mask the dyskinesia but do not address root cause; haloperidol continues to drive basal ganglia dysfunction | Risk of symptom recurrence; anticholinergic burden (urinary retention, cognitive effects) | | **Switch to SGA** | **Removes offending agent; SGAs have lower D2 occupancy and lower dyskinesia risk** | **Definitive resolution; prevents future episodes** | | Reduce haloperidol dose | Dose reduction may help, but patient has already experienced dyskinesia; lower doses still carry risk | Incomplete solution | | Add propranolol | Beta-blockers do not address basal ganglia dysfunction; no evidence for dyskinesia suppression | Ineffective | **Clinical Pearl:** Anticholinergics (benztropine, trihexyphenidyl) are appropriate for acute dystonia (neck stiffness, oculogyric crisis, jaw clenching) but are less effective for dyskinesia and carry anticholinergic side effects. For dyskinesia, agent discontinuation or switch is preferred. ### Why This Patient Needs Agent Switch 1. **Orofacial involvement** → functional impairment (speech, swallowing) 2. **Early onset** → likely to worsen with continued haloperidol 3. **SGAs available** → quetiapine, olanzapine, aripiprazole all effective for bipolar mania with lower extrapyramidal risk 4. **Reversibility window** → switching now prevents progression to tardive dyskinesia